ACP
CYT

Acuta Capital Partners’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Acuta Capital Partners’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-391,974
Closed -$4.46M – 46
2021
Q4 		$4.46M Hold
391,974
– – 1.87% 17
2021
Q3 		$6.88M Buy
391,974
+114,197
+41% +$2.13M 2.43% 13
2021
Q2 		$5.94M Buy
+277,777
New +$5.2M 2.38% 16

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acuta Capital Partners's CYT Position: Q1 2022 in Review

Acuta Capital Partners sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2022, closing a stake of 391,974 shares — an estimated $4.46M sold.

Acuta Capital Partners first reported a position in CYT in Q2 2021 and held it in 3 quarters. The position peaked at $6.88M in Q3 2021. 52 funds tracked by Wall St. Rank hold CYT as of Q1 2022.

  • Acuta Capital Partners reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 391,974 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $4.46M.
  • Acuta Capital Partners first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Acuta Capital Partners's Cyteir Therapeutics, Inc. Common Stock position peaked at $6.88M in Q3 2021.
  • 52 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Acuta Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.